Memory Rehabilitation Strategies in Patients With Multiple Sclerosis

Sponsor
I.R.C.C.S. Fondazione Santa Lucia (Other)
Overall Status
Completed
CT.gov ID
NCT05462678
Collaborator
(none)
60
2
3
38.6
30
0.8

Study Details

Study Description

Brief Summary

The clinical characteristics of MS are extremely variable from one patient to another. In about 60% of cases, motor disabilities are associated with cognitive deficits. The present study aims to compare three forms of cognitive / motor rehabilitation in three groups of patients with MS: rehabilitation of verbal memory with the Rehacom program; combined rehabilitation, associating a motor rehabilitation path with the Rehacom program; only motor rehabilitation course. Aims of the study will be: to verify whether the combined cognitive / motor rehabilitation can induce a significantly greater improvement in the memory performance of patients with MS compared to rehabilitation alone; check whether any improvement is objectively verifiable by patients and the impact it may have on patients' quality of life; monitor these effects after 6 months.

For these purposes, three homogeneous groups of 20 patients each will be enrolled, diagnosed with MS according to Mc Donald's criteria revisited by Polman (2011). The study will be divided into an initial clinical, cognitive, emotional, quality of life and functional self-perception (T0) assessment. Subsequently, the patients assigned to the three conditions will be provided with the pre-established rehabilitation treatments for a total duration of 12 weeks; at the end, each patient will undergo an overall re-evaluation (T1). Finally, a further overall reassessment will be carried out after 6 months, aimed at follow-up monitoring (T2).

Statistical analyzes will be of two types:

Within Group (aimed at assessing any improvement in the cognitive performance of each group of patients by comparing the assessments at T0 with those at T1 and T2); Between Group (aimed at comparing the results obtained by each group with those of the other 2 groups at T0, T1, and T2).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Rehabilitation
  • Behavioral: Combined Rehabilitation
  • Behavioral: Motor Rehabilitation
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Strategies and Techniques for the Rehabilitation of Memory Deficits in Patients With Multiple Sclerosis
Actual Study Start Date :
Sep 1, 2018
Actual Primary Completion Date :
Apr 20, 2021
Actual Study Completion Date :
Nov 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cognitive Rehabilitation

the first group carried out a training of CR by three memory modules of the Rehacom program (http://www.emsmedical.net).

Behavioral: Cognitive Rehabilitation
Each patient performed two weekly sessions of 45 minutes each, for 12 weeks

Experimental: Combined Training

the second group followed a mixed training program with the use of the version of the verbal memory module of the Rehacom program combined with the MR training.

Behavioral: Combined Rehabilitation
Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.

Experimental: Motor Rehabilitation

the third group carried out a traditional MR training.

Behavioral: Motor Rehabilitation
Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.

Outcome Measures

Primary Outcome Measures

  1. Pre- and Post treatment and long term cognitive efficiency [9-months]

    The primary outcome of this study is the scores on the cognitive tasks (Minimal Assessment of Cognitive Functioning in Multiple Sclerosis -MACFIMS). For MACFIMS score ranges from 1 to 3 with higher scores corresponding to higher cognitive impairment.

Secondary Outcome Measures

  1. Pre- and Post-treatment and long term motor efficiency [9-months]

    The secondary outcome of this study is the scores on the gait and balance efficiency scales (Tinetti Scale -TS); For TS the score ranges from 0 to 28 with higher scores corresponding to higher efficiency.

Other Outcome Measures

  1. Pre- and Post-treatment and long term disability and overall quality of life [9-months]

    Tertiary outcome is the scores on the self-perceived quality of life assessed with World Health Organization Disability Assessment Schedule- WHO-DAS 2. For WHO-DAS 2 total score ranges from 0 to 100, with lower scores indicate lower levels of disability e better quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of MS defined according to McDonald's diagnostic criteria revised in 2011.

  • RRMS or SPMS phenotype.

  • Language Italian mother tongue.

  • EDSS score <6.0

Exclusion Criteria:
  • Neurological or psychiatric pathologies other than MS that can interfere with cognitive functioning

  • Clinical relapses in the three months prior to enrollment

  • Severe mental illness

  • Psychiatric disorders severe enough to interfere with cognitive functioning

  • Medications Steroid therapy in the 3 months prior to enrollment

  • Motor limitations Upper limb dysfunction (paralysis or tremor) that does not allow to hold the PC mouse

  • Sensory limitations Visual acuity impaired enough to not allow reading of the instructions to the various tests

Contacts and Locations

Locations

Site City State Country Postal Code
1 Santa Lucia Foundation I.R.C.C.S. Roma Rm Italy 00179
2 I.R.C.C.S. "Santa Lucia" Foundation Rome Italy 00149

Sponsors and Collaborators

  • I.R.C.C.S. Fondazione Santa Lucia

Investigators

  • Study Director: Ugo Nocentini, MD, I.R.C.C.S. "Santa Lucia" Foundation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
I.R.C.C.S. Fondazione Santa Lucia
ClinicalTrials.gov Identifier:
NCT05462678
Other Study ID Numbers:
  • CE/PROG.698
First Posted:
Jul 18, 2022
Last Update Posted:
Jul 18, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by I.R.C.C.S. Fondazione Santa Lucia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 18, 2022